Drug Pricing
Our work in Drug Pricing
-
Spending On Targeted Therapies Reduced Mortality In Patients With Advanced-Stage Breast Cancer
Costly targeted therapies are playing an increasingly important role in treating cancer.
Categorized in -
Targeted Therapies Linked to Improved Outcomes for Advanced-Stage Breast Cancer Patients
Targeted therapies accounted for about 90% of new active substance approvals in oncology between 2011 and 2018.
Categorized in -
Don’t Make Surgery Another COVID Casualty
Investing in minimally invasive tools can free up valuable beds when pandemic surges threaten to overwhelm hospitals, argues Van Nuys and Lakdawalla in MedPage Today.
Categorized in -
Insurer Formularies Complicate the Adoption of Biosimilar Cancer Therapies
A new blog post coauthored by Schaeffer Center experts in Health Affairs finds that insurer preferences for biologic and biosimilar drugs adds cost and complicates the work of hospital pharmacists and physicians.
Categorized in -
Minimally Invasive Surgeries Offer Strategies for Hospitals to Create Surge Capacity
While COVID-19 hospitalizations are down, a new Schaeffer Center white paper highlights the importance of investing in minimally invasive technologies that will allow hospitals to prepare for future surges.
Categorized in -
Reassessing the Value of Minimally Invasive Technologies in the Era of COVID-19
Minimally invasive technologies are capacity-conserving technologies that could reduce burdens on healthcare providers and hospitals while also shielding patients from unnecessary in-hospital exposure to pathogens.
Categorized in -
The Economics of Alternative Payment Models for Pharmaceuticals
Schaeffer Center experts show how specific market inefficiencies create a role for different value-based pricing structures for pharmaceuticals.
Categorized in -
Schaeffer Solutions: Health Policy Recommendations for the Biden Administration and 117th U.S. Congress
The USC-Brookings Schaeffer Initiative for Health Policy has developed practical recommendations and analysis in a number of critical policy areas.
Categorized in -
Create a U.S. Institute of Health Technology Assessment to Preserve Innovation and Control Costs
Americans need affordable, accessible and innovative health care. An important first step that can be taken without risking heavy-handed intervention is for Congress to establish an independent Institute of Health Technology Assessment.
Categorized in -
USC Schaeffer Center and Aspen Institute Advisory Panel Recommend Ways to Modernize Health Technology Assessment in the U.S.
The U.S. has no public organization dedicated to producing and evaluating HTAs despite the potential of HTAs providing critical input about price and value, while also recognizing the contribution of innovation to advancing health and healthcare.